Assess whether biosimilarity is analytically justified (95e1c4)

Situation

Clinical-development physician owns biosimilarity is analytically justified inside an RWE group proposing a post-marketing study instead of a new RCT with biosimilar analytical similarity report as the only packet. A pediatric ethicist objecting to the proposed design is what changed the clock for this Pharma & Life Sciences CMC and Development Pathways file.

Decision

Clinical-development physician in an RWE group proposing a post-marketing study instead of a new RCT must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design.

Hypotheses to test

• The population in biosimilar analytical similarity report is the one a pediatric ethicist objecting to the proposed design named, so Proceed under protocol follows for this CMC and Development Pathways file.
• The population in biosimilar analytical similarity report is adjacent only to a pediatric ethicist objecting to the proposed design; Pause the pathway is the honest Pharma & Life Sciences call.
• An RWE group proposing a post-marketing study instead of a new RCT already contained a pediatric ethicist objecting to the proposed design before biosimilar analytical similarity report arrived; no new CMC and Development Pathways path.
• Provenance on biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design is broken; do not pick Proceed under protocol or Pause the pathway yet.

Analysis required

• Test a protocol deviation versus a safety signal versus a filing gap on biosimilarity is analytically justified.
• Check whether biosimilar analytical similarity report supports the labeled claim clinical-development physician would keep.
• Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT.
• For this Pharma & Life Sciences CMC and Development Pathways file, read biosimilar analytical similarity report against a pediatric ethicist objecting to the proposed design and write the one fact that would move biosimilarity is analytically justified for clinical-development physician.

Recommendation

Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (biosimilar analytical similarity report after a pediatric ethicist objecting to the proposed design). The follow-on CMC and Development Pathways action is what clinical-development physician does next: implement the option, assign an owner, and log the missing fact.